Justice Samuel Alito on Monday issued a one-week pause on a federal appeals court ruling that would have stripped away telehealth and mail-order access to mifepristone, the most widely used abortion drug in the United States. The move keeps the Biden-era prescribing rules in place, for now, while the Supreme Court decides whether to take up the case.
The order came after drug manufacturers rushed an emergency appeal to the high court over the weekend, arguing that the Fifth Circuit's decision had thrown the pharmaceutical and medical landscape into chaos. Alito, who handles emergency matters from the Fifth Circuit by default, paused the lower court ruling and gave the parties until Thursday to file responses.
The case now sits at the center of a legal and political collision that has been building since the Supreme Court overturned Roe v. Wade four years ago. At stake is not just how women obtain mifepristone, but whether courts can second-guess the FDA's drug-approval authority, and whether states like Louisiana can enforce their own abortion laws against a federal regulatory regime designed to override them.
The U.S. Court of Appeals for the Fifth Circuit blocked a 2023 regulation that allowed mifepristone to be prescribed through telehealth, dispensed in pharmacies, and shipped through the mail, all without an in-person doctor visit. The Biden administration had permanently ended the in-person dispensing requirement after Roe fell, a move Louisiana challenged as procedurally defective and unsupported by adequate data.
Fifth Circuit Judge Kyle Duncan wrote that the public interest did not favor preserving a medical practice "whose safety the agency admits was inadequately studied," as Breitbart reported. The appeals court found that Louisiana had standing, faced irreparable harm, and was likely to succeed on the merits of its lawsuit.
That last finding is significant. Courts do not grant preliminary relief unless the challenger shows a real probability of winning. The Fifth Circuit's conclusion that Louisiana is likely to prevail suggests serious legal vulnerabilities in the FDA's 2023 decision, vulnerabilities the Biden administration's own regulatory shortcuts may have created.
The appeals court also noted that the regulation effectively enabled out-of-state prescribers to place the drug in the hands of Louisiana residents "in defiance of Louisiana law," the Washington Examiner reported. That framing goes to the heart of federalism: can a federal agency use its regulatory power to nullify state abortion restrictions passed by elected legislatures?
Danco Laboratories, the manufacturer of mifepristone, and GenBioPro filed the emergency petition asking the Supreme Court to intervene. Danco's brief painted a picture of regulatory confusion spreading across the country.
"The panel's ruling injects immediate confusion and upheaval into highly time-sensitive medical decisions, and it forces Danco, FDA, certified Mifeprex providers, patients, and pharmacies all to guess at what is allowed and what is not."
The argument has a certain logic. Abrupt changes to prescribing rules do create uncertainty for pharmacies and providers operating under existing federal guidelines. But the confusion Danco describes is not a reason to insulate a regulation from judicial review. It is a consequence of the Biden administration's decision to push through a sweeping policy change that was always going to face legal challenge, and that the Fifth Circuit has now found was likely unlawful.
The Supreme Court has been down this road before. In 2024, the court unanimously upheld access to mifepristone, but only on a technicality, ruling that doctors and medical groups opposed to abortion lacked standing to sue. The court never reached the merits. Louisiana's lawsuit, filed by the state itself, cleared that procedural hurdle. This time, the substantive questions cannot be dodged.
Medication abortion now accounts for roughly two-thirds of all abortions in the United States, according to the Guttmacher Institute's 2023 figures. Online-only clinics provided about a quarter of all clinician-provided abortions in 2025. The FDA first approved mifepristone more than 20 years ago, and its website continues to say the drug is safe and effective for use up to 10 weeks of gestation.
Those numbers explain why the abortion industry treated the Fifth Circuit ruling as an emergency. The mail-order pipeline is not a sideshow. It is the primary delivery mechanism for abortion services in much of the country, and it was built on a regulatory foundation that a federal appeals court has now found to be legally suspect.
The Supreme Court has been an active force this term across multiple fronts. Its recent landmark ruling striking down Louisiana's race-based congressional map showed the justices' willingness to intervene decisively on questions of law, even when the political stakes are high.
Louisiana Attorney General Liz Murrill, a Republican, did not flinch at the Supreme Court's procedural pause. She framed the stakes in blunt terms.
"Big abortion pharma claims they need an emergency stay because they will lose massive amounts of money if they can't kill more babies quickly and efficiently by mail without medical oversight."
Murrill added that the administrative stay was temporary and expressed confidence that "life and the law will win in the end."
Her language was pointed, but her legal position rests on a straightforward argument: the FDA removed the in-person dispensing requirement through a process that had procedural defects and lacked sufficient supporting data. If that claim holds up, the entire mail-order abortion infrastructure built since 2023 sits on sand.
The broader political context is worth noting. California Democrats have not taken recent Supreme Court rulings well, and this case is likely to generate similar reactions from abortion-rights advocates who have grown accustomed to treating FDA approval as a permanent shield against state regulation.
Alito's pause runs through at least May 11 at 5 p.m., Fox News reported, while the court considers whether to extend the stay and potentially take up the case on the merits. The parties must respond by Thursday. Alito could ultimately refer the matter to the full court for a vote.
Senate Minority Leader Chuck Schumer called the stay a good sign for access but acknowledged the fight was "just beginning." Pro-life groups saw it differently. SBA Pro-Life America President Marjorie Dannenfelser called the underlying Fifth Circuit ruling "a huge victory for victims and survivors of Biden's reckless mail-order abortion drug regime," Just The News reported.
The procedural posture matters. An administrative stay is not a ruling on the merits. It is a brief pause to let the justices study the case. But the fact that the Fifth Circuit found Louisiana likely to succeed, and that the Supreme Court's 2024 decision dodged the substance entirely, means the legal ground under the mail-order abortion regime is far less settled than its defenders pretend.
The case also raises questions that extend well beyond abortion. If the FDA can unilaterally strip away in-person prescribing requirements for a drug that ends a pregnancy, what limits exist on its authority to reshape medical practice by regulatory fiat? The Supreme Court's willingness to reshape the legal landscape on other fronts this term suggests the justices may be ready to answer that question.
Louisiana's lawsuit also tests a principle that should matter to anyone who believes in self-governance. The state passed laws restricting abortion. The Biden administration's FDA then adopted rules that effectively allowed out-of-state providers to circumvent those laws by mailing pills across state lines. The Fifth Circuit recognized that conflict. Whether the Supreme Court will do the same remains the open question.
States that have moved quickly to assert their authority in other legal arenas are watching this case closely. A ruling that the FDA can override state law through administrative action would set a precedent reaching far beyond abortion.
The abortion industry built a massive mail-order distribution network on the back of a single regulatory change, one that a federal appeals court has now found was likely adopted without adequate process or data. Danco Laboratories and its allies are asking the Supreme Court to keep that network running while the legal challenge plays out. Louisiana is asking the court to let the law take its course.
Alito's one-week pause buys time. It does not resolve anything. The justices will soon have to decide whether the FDA's authority to approve drugs also includes the power to dictate how, where, and by whom those drugs are dispensed, even when state law says otherwise.
When a federal agency builds a policy on a shortcut, it should not be surprised when a court calls the shortcut what it is.